` 000627 (Hubei Biocause Pharmaceutical Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

000627
vs
Shanghai Composite

Over the past 12 months, has significantly outperformed Shanghai Composite, delivering a return of 55% compared to the Shanghai Composite's 12% growth.

Stocks Performance
000627 vs Shanghai Composite

Loading

Performance Gap
000627 vs Shanghai Composite

Loading
000627
Shanghai Composite
Difference

Performance By Year
000627 vs Shanghai Composite

Loading
000627
Shanghai Composite
Add Stock

Competitors Performance
Hubei Biocause Pharmaceutical Co Ltd vs Peers

Shanghai Composite
000627
601318
601628
1299
AFL
Add Stock

Hubei Biocause Pharmaceutical Co Ltd
Glance View

Market Cap
19.9B CNY
Industry
Insurance

Hubei Biocause Pharmaceutical Co., Ltd began its journey in the health sector by positioning itself strategically in the pharmaceutical industry. With its headquarters set in the Hubei Province of China, this company has intricately woven itself into the fabric of modern healthcare. Primarily, it thrives by developing, manufacturing, and distributing a variety of pharmaceutical products including both traditional and modern-medicine drugs. The journey of Biocause is punctuated by its research-driven approach, which focuses on innovation and quality control across its production lines, ensuring it stays at the forefront of pharmaceutical advancements. Revenue generation for Hubei Biocause predominantly comes from the sale of medications and healthcare products, but the company's financial tapestry is more diversified. It has explored opportunities by extending its business horizon beyond pharmaceuticals, tapping into other ventures such as insurance services. This diversification has enabled Biocause to stabilize its financial structure and mitigate risk, leveraging its steady pharma income to branch into realms that complement its healthcare base. Alongside, their strategic partnerships and alliances further bolster their market position, allowing for a broadened geographical reach and a more substantial impact on the sectors they operate within. Thus, Hubei Biocause crafts a story not only of pharmaceutical excellence but of strategic breadth that spawns wider market opportunities.

Intrinsic Value
4.98 CNY
Undervaluation 19%
Intrinsic Value
Price
H
Back to Top